uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $25.00 target price on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 393.10% from the stock’s current price.

A number of other research firms also recently issued reports on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Friday, March 1st. Mizuho dropped their price objective on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday. The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and reduced their target price for the company from $63.00 to $8.00 in a report on Thursday, February 29th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price target on shares of uniQure in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.91.

uniQure Stock Performance

Shares of QURE stock opened at $5.07 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The firm has a market capitalization of $242.54 million, a price-to-earnings ratio of -0.78 and a beta of 0.98. uniQure has a one year low of $4.25 and a one year high of $22.48. The company has a 50 day moving average price of $4.98 and a 200 day moving average price of $5.88.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The company had revenue of $6.69 million during the quarter, compared to analysts’ expectations of $3.20 million. Sell-side analysts anticipate that uniQure will post -4.49 EPS for the current year.

Insider Transactions at uniQure

In related news, COO Pierre Caloz sold 9,455 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the transaction, the chief operating officer now owns 85,643 shares of the company’s stock, valued at $554,110.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other uniQure news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 27,904 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,265 shares of company stock valued at $339,845. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently modified their holdings of the stock. Raymond James & Associates grew its stake in uniQure by 6.4% in the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of uniQure by 58.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 3,664 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of uniQure in the 3rd quarter worth approximately $31,000. Harbor Capital Advisors Inc. increased its holdings in shares of uniQure by 21.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 5,389 shares during the last quarter. Finally, Pale Fire Capital SE raised its position in shares of uniQure by 9.2% during the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after acquiring an additional 5,500 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.